Medicalgorithmics S.A. — Regulatory Filings 2023

Apr 4, 2023

Subject:Medicalgorithmics subsidiary Kardiolytics' VCAST technology receives newU.S. patent for autonomous segmentation using artificial intelligencefor vascular disease diagnosis

Currentreport no.:10/2023

Dateof preparation:April 3, 2023.

Legalbasis:Article 17 par. 1 of the MAR Regulation - confidential information.

TheManagement Board of Medicalgorithmics S.A. headquartered in Warsaw(_quot;Company_quot;) announces that its wholly-owned subsidiary, KardiolyticsInc. (_quot;Kardiolytics_quot;), has been granted USA Patent No. 11626211. TheCompany has received notification from the United States Patent andTrademark Office on April 3, 2023, and the patent is expected to bepublished on or around April 11, 2023.

Thepatent concerns an autonomous methodformodelling blood vessels and blood flowusinga CT angiography scan. The method involves generating athree-dimensional personalized model of the blood vessels and athree-dimensional reference model of healthy blood vessels that lacklesions. The personalized model is then subjected to a numericalsimulation of blood flow under the same physical and boundary conditionsas the reference model. The simulation involves determining theconditions of blood flow at the inlet of the blood vessels model andcalculating the energy of the blood flow for the inlet and all outletsof the model. The blood flow energy measured for the personalized modeland the reference model are compared to determine flow energy changeindexes. This method can be used to assess the impact of lesions orother abnormalities on blood flow and could potentially be used todiagnose or monitor vascular diseases.

Thisis the next patent obtained by Kardiolytics. Securing patents forinnovations and technologies will enable Kardiolytics to promote andcommercialize inventions, including its VCAST technology. Also, what isof the greatest importance - it will help protect Kardiolytics' uniqueintellectual property to enable further development of the solution andimprove CAD diagnostics (Coronary Artery Disease - the most common heartdisease in the US).

Kardiolytics,a company creating solutions for medicine based on artificialintelligence, joined the Medicalgorithmics capital group in November2022.

TheIssuer's Management is publishing this information as it aligns with theplan outlined in current report no. 58/2022.